Spark Therapeutics Inc. (ONCE) and Chiasma Inc. (NASDAQ:CHMA) Comparing side by side

Both Spark Therapeutics Inc. (NASDAQ:ONCE) and Chiasma Inc. (NASDAQ:CHMA) are Biotechnology companies, competing one another. We will contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spark Therapeutics Inc. 64.72M 66.56 78.82M -1.70 0.00
Chiasma Inc. N/A 0.00 31.26M -1.16 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Spark Therapeutics Inc. and Chiasma Inc.


Table 2 represents Spark Therapeutics Inc. (NASDAQ:ONCE) and Chiasma Inc. (NASDAQ:CHMA)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Spark Therapeutics Inc. -121.79% -17.5% -12.9%
Chiasma Inc. 0.00% -56.3% -48.6%

Volatility and Risk

A 2.63 beta indicates that Spark Therapeutics Inc. is 163.00% more volatile compared to S&P 500. Chiasma Inc.’s 1.42 beta is the reason why it is 42.00% more volatile than S&P 500.


Spark Therapeutics Inc.’s Current Ratio is 10.7 while its Quick Ratio is 10.4. On the competitive side is, Chiasma Inc. which has a 5.6 Current Ratio and a 5.6 Quick Ratio. Spark Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Chiasma Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Spark Therapeutics Inc. and Chiasma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Spark Therapeutics Inc. 0 9 3 2.25
Chiasma Inc. 0 0 2 3.00

The downside potential is -21.30% for Spark Therapeutics Inc. with average price target of $89.39. Competitively Chiasma Inc. has an average price target of $13.5, with potential upside of 104.86%. The data from earlier shows that analysts view suggest that Chiasma Inc. seems more appealing than Spark Therapeutics Inc.

Institutional & Insider Ownership

Roughly 0% of Spark Therapeutics Inc. shares are held by institutional investors while 70.6% of Chiasma Inc. are owned by institutional investors. Spark Therapeutics Inc.’s share held by insiders are 1.6%. Comparatively, insiders own roughly 0.3% of Chiasma Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Spark Therapeutics Inc. -0.39% 136.39% 166.42% 81.71% 88.06% 188.81%
Chiasma Inc. 18.45% 35.71% 19.35% 97.92% 206.45% 52.73%

For the past year Spark Therapeutics Inc. has stronger performance than Chiasma Inc.


On 6 of the 11 factors Spark Therapeutics Inc. beats Chiasma Inc.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of a form of Batten disease and Huntington's disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and SPK-LHON for treating Leber hereditary optic neuropathy, as well as preclinical programs in development for the treatment of rare genetic blinding conditions, hematologic disorders, and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.